DE69434951D1 - Heterologe antigene in stämmen zur impfung mit lebendzellen - Google Patents

Heterologe antigene in stämmen zur impfung mit lebendzellen

Info

Publication number
DE69434951D1
DE69434951D1 DE69434951T DE69434951T DE69434951D1 DE 69434951 D1 DE69434951 D1 DE 69434951D1 DE 69434951 T DE69434951 T DE 69434951T DE 69434951 T DE69434951 T DE 69434951T DE 69434951 D1 DE69434951 D1 DE 69434951D1
Authority
DE
Germany
Prior art keywords
heterologist
antigenes
vaccination
trees
living cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69434951T
Other languages
English (en)
Inventor
Stephen B Calderwood
Joan R Butterton
John J Mekalanos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard College
General Hospital Corp
Original Assignee
Harvard College
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College, General Hospital Corp filed Critical Harvard College
Application granted granted Critical
Publication of DE69434951D1 publication Critical patent/DE69434951D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/107—Vibrio
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/25—Shigella (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/28—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Vibrionaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
DE69434951T 1993-02-22 1994-02-22 Heterologe antigene in stämmen zur impfung mit lebendzellen Expired - Lifetime DE69434951D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2050193A 1993-02-22 1993-02-22
PCT/US1994/001780 WO1994019482A1 (en) 1993-02-22 1994-02-22 Heterologous antigens in live cell vaccine strains

Publications (1)

Publication Number Publication Date
DE69434951D1 true DE69434951D1 (de) 2007-05-24

Family

ID=21798955

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69434951T Expired - Lifetime DE69434951D1 (de) 1993-02-22 1994-02-22 Heterologe antigene in stämmen zur impfung mit lebendzellen

Country Status (8)

Country Link
US (1) US5747028A (de)
EP (1) EP0692031B1 (de)
JP (1) JPH08506963A (de)
AT (1) ATE359370T1 (de)
AU (1) AU683454B2 (de)
CA (1) CA2156191A1 (de)
DE (1) DE69434951D1 (de)
WO (1) WO1994019482A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9326174D0 (en) * 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
WO1996000233A1 (en) * 1994-06-24 1996-01-04 Children's Hospital And Medical Center Escherichia coli o157:h7 epithelial adhesin
JPH11507532A (ja) * 1995-06-07 1999-07-06 ワシントン ユニバーシティ 環境に制限される生存能を有する組換え細菌システム
WO1998010064A1 (en) * 1996-09-06 1998-03-12 Commonwealth Scientific And Industrial Research Organisation Iron regulated promoter and uses thereof
US6036953A (en) * 1996-11-29 2000-03-14 The General Hospital Corporation Heterologous antigens in live cell V. cholerae strains
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
EP0887403A3 (de) * 1997-06-27 2000-12-06 Chiron S.P.A. Abgeschwächte Stämme von Vibrio cholerae
FR2766193B1 (fr) * 1997-07-18 2001-09-14 Inst Curie Polypeptide chimerique comprenant le fragment b de la toxine shiga et des peptides d'interet therapeutique
PT1035863E (pt) 1997-12-05 2006-07-31 Virginia Tech Intell Prop Vacina de antigenio homologo sobre-expressante e um metodo para produzir a mesma
CU22661A1 (es) * 1997-12-30 2001-04-27 Cnic Ct Nac Investigaciones Nuevos candidatos vacunales de vibrio cholerae y método de obtención
ES2255269T3 (es) * 1998-05-15 2006-06-16 Institut Curie Subunidad b de la verotoxina para inmunizacion.
SE9801852D0 (sv) * 1998-05-26 1998-05-26 Sbl Vaccin Ab Method of producing thy A-strains of Vibro cholerae, suck strains and their use
EP1105490A1 (de) 1998-08-20 2001-06-13 Aventis Pasteur Limited Einschlussmembranprotein c von chlamydia kodierende nukleinsäuremoleküle
US6693087B1 (en) 1998-08-20 2004-02-17 Aventis Pasteur Limited Nucleic acid molecules encoding POMP91A protein of Chlamydia
US6686339B1 (en) 1998-08-20 2004-02-03 Aventis Pasteur Limited Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia
EP1228095B1 (de) 1999-10-22 2008-04-09 Sanofi Pasteur Limited Modifiziertes gp100 und dessen verwendung
US8153414B2 (en) 2000-04-06 2012-04-10 Allertein Therapeutics, Llc Microbial delivery system
EP1792995A3 (de) 2000-05-08 2007-06-13 Sanofi Pasteur Limited Chlamydia Antigene, entsprechende DNS Fragmente und ihre Verwendungen
ES2276788T3 (es) 2000-05-10 2007-07-01 Sanofi Pasteur Limited Polipeptidos inmunogenos codificados por minigenes mage y sus utilizaciones.
US6541013B1 (en) 2000-07-13 2003-04-01 Idaho Research Foundation, Inc. Methods and compositions for suppressing bovine leukemia virus with a Shiga toxin polypeptide
US7135173B2 (en) * 2000-07-13 2006-11-14 Idaho Research Foundation, Inc. Antiviral activity of Shiga toxin
EP1343894A4 (de) 2000-11-02 2005-05-04 Univ Singapore Aopb-gen, -protein, homologe, fragmente und varianten davon und ihre verwendung bei der zelloberflächenpräsentation
EP1864691B1 (de) 2002-04-09 2011-07-20 Sanofi Pasteur Limited Modifizierte CEA-Nukleinsäure und entsprechende Expressionsvektoren
WO2004024067A2 (en) * 2002-09-10 2004-03-25 Vical Incorporated Codon-optimized polynucleotide-based vaccines against bacillus anthracis infection
KR101162970B1 (ko) * 2003-10-08 2012-07-12 테리온 바이오로직스, 인크. 변형된 ｃｅａ/ｂ7 벡터
EP3187585A1 (de) 2010-03-25 2017-07-05 Oregon Health&Science University Cmv-glycoproteine und rekombinante vektoren
WO2012170765A2 (en) 2011-06-10 2012-12-13 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (de) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
EP3503915B1 (de) * 2016-08-26 2024-02-21 Telesis Bio Inc. Genetisch modifizierte vibrio natriegens
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4882278A (en) * 1983-04-29 1989-11-21 President And Fellows Of Harvard College Non-toxinogenic vibrio cholerae mutants
EP0251579A3 (de) * 1986-06-24 1989-03-22 Enterovax Research Pty. Ltd. Markiersystem ohne Antibiotika
EP0257837A1 (de) * 1986-08-19 1988-03-02 Enterovax Research Pty. Ltd. Hybrider Bakterienstamm
US5112749A (en) * 1987-10-02 1992-05-12 Praxis Biologics, Inc. Vaccines for the malaria circumsporozoite protein
GB8730037D0 (en) * 1987-12-23 1988-02-03 Wellcome Found Vaccines
FR2636842B1 (fr) * 1988-09-27 1994-06-10 Liege Universite Etat Proteine de fusion d'une sequence derivee de la sous-unite b de la toxine cholerique et d'un antigene heterologue doue de proprietes immunogenes, compositions de vaccins les contenant et acides nucleiques recombinants contenant une sequence de nucleotides codant pour ladite proteine de fusion
WO1991018092A1 (en) * 1990-05-23 1991-11-28 University Of Maryland At Baltimore Acid-tolerant salmonella typhi, double aro mutants thereof and use as an oral vaccine for typhoid fever
DE69221120T2 (de) * 1992-04-10 1998-02-26 Schweiz Serum & Impfinst Rekombinanter lebender Impfstoff gegen Gram-negative enterische Pathogene
US5330754A (en) * 1992-06-29 1994-07-19 Archana Kapoor Membrane-associated immunogens of mycobacteria
DE69333028T2 (de) * 1992-07-06 2004-04-22 The President And Fellows Of Harvard College, Cambridge Deletionsmutanten als impfstoffe gegen cholera

Also Published As

Publication number Publication date
AU683454B2 (en) 1997-11-13
CA2156191A1 (en) 1994-09-01
EP0692031B1 (de) 2007-04-11
WO1994019482A1 (en) 1994-09-01
JPH08506963A (ja) 1996-07-30
US5747028A (en) 1998-05-05
EP0692031A1 (de) 1996-01-17
EP0692031A4 (de) 1997-11-19
ATE359370T1 (de) 2007-05-15
AU6244594A (en) 1994-09-14

Similar Documents

Publication Publication Date Title
DE69434951D1 (de) Heterologe antigene in stämmen zur impfung mit lebendzellen
HU9203098D0 (en) Living vaccine
SE8300693L (sv) Sett att framstella och isolera proteiner och polypeptider samt en hybridvektor for detta
NZ190524A (en) Recombinant dna method for producing specific protein or polypeptide cleaving of bacterial gene for extracellular or periplasmic carrier protein
FI933757A0 (fi) Expression av rekombinantproteiner i attenuerade bakterier
ATE359084T1 (de) Modifizierter hitzeschockprotein/peptidantigen komplex
DE69632536D1 (de) Impfstoffe für das respiratorische-synzytial-virus mit nuklein säuren
DE69132814D1 (de) Neues insulinähnliches wachstumsfaktor bindendes protein igfbp-5
GB9409985D0 (en) Vaccine against mycobacterial infections
AU2795989A (en) Production of gonorrheal pi proteins and vaccines
AU612683B2 (en) Synthetic peptides, antibodies directed against them, and the use thereof
CN103479996A (zh) 一种副猪嗜血杆菌病亚单位疫苗组合物及应用
ATE89317T1 (de) Proteine, expressionsvektoren, die fuer solche proteine kodierende dna enthalten und zellen, die solche expressionsvektoren enthalten.
DE68916424T2 (de) Pasteurella-impfstoff.
DK0629238T3 (da) Autotaxin:Motilitetsstimulerende protein, som er nyttigt til cancerdiagnose og terapi
DE69233155D1 (de) Insulinartigen wachstumsfaktor bindendes protein
EA199600001A3 (ru) Агент экстракции периплазматических рекомбинантных белков, способ экстракции периплазматического белка и способ культивирования прокариотического микроорганизма
AU1541595A (en) Expression of heterologous proteins in attenuated bacteria using the htra-promoters
DK230890A (da) Dna-fragment, der koder for et pasteurella multocida-toxin eller for en subsekvens eller analog deraf, ekspressionsvektor, der omfatter dna-fragmentet, mikroorganisme, der udtrykker dette, fremgangsmaade til fremstilling af et pasteurella-multocida-toxin, diagnostisk middel samt anvendelse heraf, vaccine indeholdende et pasteurella-multocida-toxinderivat, anvendelse af pasteurella multocida-t m.m.
Cohen et al. FOR THE| N| VITRO CULTIVATION OF TRYPANOSOMA CRUZI

Legal Events

Date Code Title Description
8332 No legal effect for de